Blood irradiation therapy | |
---|---|
Specialty | Hematology |
This article is part of a series on |
Alternative medicine |
---|
Blood irradiation therapy is an alternative medical procedure in which the blood is exposed to low-level light (often laser light) for therapeutic reasons. [1] The practice was originally developed in the United States, [1] but most recent research on it has been conducted in Germany (by UV lamps) and in Russia (in all variants). [2] [3] [4] [5] Low-level laser therapy has been tested for a wide range of conditions, but rigorous double-blinded studies have not yet been performed. [6] Furthermore, it has been claimed that ultraviolet irradiation of blood kills bacteria by DNA damage and also activation of the immune system. Blood irradiation therapy is highly controversial, and has fallen from mainstream use since its heyday in the 1940s and 1950s. [1]
Blood irradiation therapy can be administered in three ways: extracorporeally, transcutaneously, and intravenously. The extracorporeal (outside the body) method removes blood from the body and irradiates it in a special cuvette (tube). This method is used for the ultraviolet (UV) blood irradiation (UVBI) by UV lamps. In the transcutaneous method, the radiation goes through the skin, by placing a device on the outside of the skin. In the intravenous method, a device is inserted into a large blood vessel. The laser light is monochromatic.
It is not related to the practice of gamma irradiation of blood in transfusion medicine.
In 1928, Dr. Emmet Knott and a medical student named Lester Edblom received a United States patent for a "Means for Treating Blood-Stream Infection" that incorporated a rudimentary ultraviolet bulb, vacuum extraction system and a cuvette. The "Knott Hemo-Irradiator" was used from the 1930s through the 1950s on patients with multiple infectious diseases.
George P Miley at the Hahnemann Hospital in Philadelphia, Pennsylvania, published a series of articles on the use of the procedure in the treatment of thrombophlebitis, staphylococcal sepsis, peritonitis, botulism, poliomyelitis, non-healing wounds, and asthma.
One of the best known and most comprehensive set of studies was published in 1947 by Dr. George Miley and Dr. Jens A Christensen (from the Blood Irradiation Clinic of the Hahnemann Medical College and Hospital of Philadelphia, Pennsylvania). The authors studied 445 cases of acute pyogenic infections and 74 cases of virus and virus-like infections. Findings included the following: sulfonamide-resistant and penicillin-resistant infections have responded to the treatment. Further finding included: "We have observed that toxemias due to various virus and virus-like infections subside rapidly …” Some of the more impressive results included cases involving septic infection, 57 out of 57 cases recovered. In treating peritonitis, 16 out of 18 patients recovered. With puerperal sepsis, 14 out of 14 patients recovered. With thrombophlebitis, 34 out of 34 recovered. The authors emphasized the need to follow the protocol set for by Knott. Of importance, this protocol included the use of a chamber or cuvette with a flat quartz surface.
Henry A Barrett at the Willard Parker Hospital in New York City, in 1940 reported on 110 cases including a number of infections. Twenty-nine different conditions were described as responding including the following: infectious arthritis, septic abortion, osteoarthritis, tuberculosis glands, chronic blepharitis, mastoiditis, uveitis, furunculosis, chronic paranasal sinusitis, acne vulgaris, and secondary anemia. [7]
This procedure fell out of favor in the late 1950s, at a time when antibiotics and the polio vaccine were becoming widely used. [7] Since then it has been sidelined as a type of alternative and complementary medicine. [1]
The U.S. Food and Drug Administration (FDA) has approved one type of this treatment [8] [9] for T cell lymphoma. This particular process was developed by a team at Yale, led by Richard Edelson who developed a photopheresis machine. This machine separates the white and red blood cells. The white cells are then routed into a blood chamber, where those cells are subjected to UV light from the UVA part of the spectrum. This process uses a photosensitizing agent which enhances the effectiveness of the light. [10] Observational evidence suggests that photopheresis might be effective in the treatment of graft-versus-host disease, [11] though controlled trials are needed to support this use. [12] [13]
The American Cancer Society lists blood irradiation therapy as one of many types of ineffective cancer treatment fraudulently sold by alternative cancer treatment clinics in Mexico. [14]
Intravenous or intravascular laser blood irradiation (ILBI) involves the in-vivo illumination of the blood by feeding low level laser light generated by a 1–3 mW helium–neon laser at a wavelength of 632.8 nanometers (nm) into a vascular channel, usually a vein in the forearm, under the assumption that any therapeutic effect will be circulated through the circulatory system. [15] Most often wavelengths of 365, 405, 525 and 635 nm and power of 2.3 mW are used. The technique is widely used at present in Russia, less in Asia, and not extensively in other parts of the world. It is shown that ILBI improves blood flow and its transport activities, therefore, tissue tropism, has a positive effect on the immune system and cell metabolism. [2] [3] [ better source needed ] This issue is subject to skepticism. [2]
Transcutaneous therapy applies laser light on unbroken skin in areas with large numbers of blood vessels (such as the forearm). Because of the skin acting as a barrier to the blood, absorbing low level laser energy, the power of the laser is often boosted to compensate. [16] The problem can be solved by using pulsed matrix laser light sources. [3]
Extracorporeal irradiation is used only for ultraviolet blood irradiation, that involves drawing blood out through a vein and irradiating it outside of the body. [17]
Though promoted as a treatment for cancer, a 1952 review in the Journal of the American Medical Association [4] and another review by the American Cancer Society in 1970 concluded the treatment was ineffective. [18]
Neutropenia is an abnormally low concentration of neutrophils in the blood. Neutrophils make up the majority of circulating white blood cells and serve as the primary defense against infections by destroying bacteria, bacterial fragments and immunoglobulin-bound viruses in the blood. People with neutropenia are more susceptible to bacterial infections and, without prompt medical attention, the condition may become life-threatening.
Photodynamic therapy (PDT) is a form of phototherapy involving light and a photosensitizing chemical substance used in conjunction with molecular oxygen to elicit cell death (phototoxicity).
Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood, in order to replicate inside a patient and produce additional normal blood cells. HSCT may be autologous, syngeneic, or allogeneic.
Graft-versus-host disease (GvHD) is a syndrome, characterized by inflammation in different organs. GvHD is commonly associated with bone marrow transplants and stem cell transplants.
Light therapy, also called phototherapy or bright light therapy is the exposure to direct sunlight or artificial light at controlled wavelengths in order to treat a variety of medical disorders, including seasonal affective disorder (SAD), circadian rhythm sleep-wake disorders, cancers, and skin wound infections. Treating skin conditions such as neurodermatitis, psoriasis, acne vulgaris, and eczema with ultraviolet light is called ultraviolet light therapy.
An extracorporeal procedure is a medical procedure which is performed outside the body. Extracorporeal devices are the artificial organs that remain outside the body while treating a patient. Extracorporeal devices are useful in hemodialysis and cardiac surgery.
Mycosis fungoides, also known as Alibert-Bazin syndrome or granuloma fungoides, is the most common form of cutaneous T-cell lymphoma. It generally affects the skin, but may progress internally over time. Symptoms include rash, tumors, skin lesions, and itchy skin.
An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumour. Oncolytic viruses are thought not only to cause direct destruction of the tumour cells, but also to stimulate host anti-tumour immune system responses. Oncolytic viruses also have the ability to affect the tumor micro-environment in multiple ways.
Virotherapy is a treatment using biotechnology to convert viruses into therapeutic agents by reprogramming viruses to treat diseases. There are three main branches of virotherapy: anti-cancer oncolytic viruses, viral vectors for gene therapy and viral immunotherapy. These branches use three different types of treatment methods: gene overexpression, gene knockout, and suicide gene delivery. Gene overexpression adds genetic sequences that compensate for low to zero levels of needed gene expression. Gene knockout uses RNA methods to silence or reduce expression of disease-causing genes. Suicide gene delivery introduces genetic sequences that induce an apoptotic response in cells, usually to kill cancerous growths. In a slightly different context, virotherapy can also refer more broadly to the use of viruses to treat certain medical conditions by killing pathogens.
In medicine, photopheresis is a form of apheresis and photodynamic therapy in which blood is subject to apheresis to separate buffy coat from whole blood, chemically treated with 8-methoxypsoralen, exposed to ultraviolet light (UVA), and then returned to the patient. Activated 8-methoxypsoralen crosslinks DNA in exposed cells, ultimately resulting apoptosis of nucleated cells. The photochemically damaged T-cells returned to the patient appear to induce cytotoxic effects on T-cell formation. The mechanism of such “antitumor” action has not been elucidated.
Ultraviolet germicidal irradiation (UVGI) is a disinfection technique employing ultraviolet (UV) light, particularly UV-C (180–280 nm), to kill or inactivate microorganisms. UVGI primarily inactivates microbes by damaging their genetic material, thereby inhibiting their capacity to carry out vital functions.
A medical procedure is a course of action intended to achieve a result in the delivery of healthcare.
Low-level laser therapy (LLLT), cold laser therapy, photobiomodulation (PBM) or red light therapy is a form of medicine that applies low-level (low-power) lasers or light-emitting diodes (LEDs) to the surface of the body. Whereas high-power lasers are used in laser medicine to cut or destroy tissue, it is claimed that application of low-power lasers relieves pain or stimulates and enhances cell function. The effects appear to be limited to a specified set of wavelengths and new research has demonstrated effectiveness at myopia control. Several such devices are cleared by the United States Food and Drug Administration (FDA), and research shows potential for treating a range of medical problems including rheumatoid arthritis and oral mucositis.
Indocyanine green (ICG) is a cyanine dye used in medical diagnostics. It is used for determining cardiac output, hepatic function, liver and gastric blood flow, and for ophthalmic and cerebral angiography. It has a peak spectral absorption at about 800 nm. These infrared frequencies penetrate retinal layers, allowing ICG angiography to image deeper patterns of circulation than fluorescein angiography. ICG binds tightly to plasma proteins and becomes confined to the vascular system. ICG has a half-life of 150 to 180 seconds and is removed from circulation exclusively by the liver to bile.
Pathogen reduction using riboflavin and UV light is a method by which infectious pathogens in blood for transfusion are inactivated by adding riboflavin and irradiating with UV light. This method reduces the infectious levels of disease-causing agents that may be found in donated blood components, while still maintaining good quality blood components for transfusion. This type of approach to increase blood safety is also known as “pathogen inactivation” in the industry.
Immunoglobulin therapy is the use of a mixture of antibodies to treat several health conditions. These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a more specific immunoglobulin is not available. Depending on the formulation it can be given by injection into muscle, a vein, or under the skin. The effects last a few weeks.
Andrew Louis Pecora is an American hematologist and oncologist involved in research on the use of stem cells and oncolytic viruses to treat diseases, including cancer. He is the CEO of Outcomes Matter Innovations. As of 2020, he is on the Board of Directors Celularity, Inc. (since 2017) and founder and Executive Chairman, COTA, Inc.. Previously, he was chief innovations officer, professor and vice president of cancer services at the John Theurer Cancer Center, part of the Hackensack University Medical Center. He is a professor of medicine and oncology at Georgetown University.
Intravenous Ascorbic Acid or PAA, pharmacologic ascorbic acid, is a process that delivers soluble ascorbic acid directly into the bloodstream. It is not approved for use to treat any medical condition.
Richard Edelson is the Anthony Brady Professor of Dermatology at the Yale School of Medicine. He is a past director of the Yale Cancer Center, and an elected fellow of both the American Society for Clinical Investigation and the Association of American Physicians. He is known for his research discoveries in non-Hodgkins lymphoma, particularly his early career introduction of the disease category concept of Cutaneous T Cell Lymphoma (CTCL), and his discovery of extracorporeal photochemotherapy (ECP) as an immunotherapy for cancer, transplant reactions and autoimmunity.